AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

ABSTRACT:

Background

The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone.

Methods

We used a quantitative reverse-transcriptase-polymerase-chain-reaction assay to evaluate AR-V7 in circulating tumor cells from prospectively enrolled patients with metastatic castration-resistant prostate cancer who were initiating treatment with either enzalutamide or abiraterone. We examined associations between AR-V7 status (posit

SUBMITTER: Antonarakis ES 

PROVIDER: S-EPMC4201502 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature